Montreal-based Mimetogen Pharmaceuticals has closed a series B financing round to further develop its neurotrophin mimetics to treat dry eye and other degenerative ocular disorders. The financing is provided by Medwell Capital Inc, which is committing up to $2-million in the privately held, clinical-stage spin off from McGill Univ and Lady Davis Institute for Medical Research. Undisclosed amounts are also being provided by follow-on investors iNovia Capital, MSBi Valorisation and VIMAC Milestone Medica. The funding will allow Mimetogen to complete its Phase II clinical study of MIM-D3 for treatment of moderate to severe dry eye disease….